Target intelligence / Profile preview

Trigeminal nerve endings, nasal chemoreceptors, and mucociliary apparatus in nasal mucosa

Molecular classification
Other
01

Overview

The nasal mucosa integrates several distinct physiological systems, including trigeminal nerve endings, chemoreceptors, and the mucociliary apparatus, which collectively serve as the primary defense for the upper respiratory tract. The trigeminal nerve (CN V) provides extensive sensory innervation, detecting mechanical, thermal, and chemical irritants (chemesthesis) through molecular sensors like TRPV1 and TRPA1 channels (Silver et al., 2006, 'The Trigeminal System in the Nasal Cavity'). Nasal chemoreceptors, including solitary chemosensory cells, monitor the chemical environment and can trigger protective reflexes such as sneezing or changes in respiratory rate (Tizzano et al., 2010, 'Nasal solitary chemosensory cells'). The mucociliary apparatus consists of ciliated epithelial cells and a mucus layer that traps inhaled particles and pathogens, transporting them toward the pharynx for clearance (Bustamante-Marin & Ostrowski, 2017, 'Cilia and Mucociliary Clearance'). While this composite is not a single molecular target, its individual components are targeted by various pharmacological agents, such as decongestants, anticholinergics, and TRP channel modulators, to treat conditions like allergic rhinitis and chronic sinusitis. This system is critical for maintaining airway homeostasis and protecting the lungs from environmental insults.

Other names
Nasal trigeminal sensory systemNasal chemosensory apparatusNasal mucociliary clearance systemNasal airway defense system
02

Mechanism of action

Activation of transient receptor potential (TRP) channels on nerve endings, agonism of alpha-adrenergic receptors for vasoconstriction, antagonism of muscarinic receptors to reduce secretions, and physical hydration or enzymatic breakdown of mucus to facilitate clearance.

03

Biological functions

Sensory perceptionChemoreceptionMucociliary clearanceDefense mechanismThermoregulationSignal transduction
04

Disease associations

InflammationInfectionRhinitisSinusitisCystic fibrosisPrimary ciliary dyskinesia
05

Safety considerations

Rhinitis medicamentosa (rebound congestion)Nasal mucosal atrophyEpistaxisAnosmia (loss of smell)Ciliary toxicityTrigeminal sensitization
06

Interacting drugs

Capsaicin

6 more in the full profile.

07

Biomarkers

Saccharin transit timeCiliary beat frequency (CBF)Nasal pungency thresholdNasal nitric oxide levels

Beyond the preview

Go deeper on Trigeminal nerve endings, nasal chemoreceptors, and mucociliary apparatus in nasal mucosa.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Trigeminal nerve endings, nasal chemoreceptors, and mucociliary apparatus in nasal mucosa.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call